Key Stats for Novo Nordisk Stock
- 1- Year Price change for Novo Nordisk stock: -39%
- $NVO Share Price as of Feb. 3: $50
- 52-Week High: $94
- $NVO Stock Price Target: $59
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Novo Nordisk (NVO) stock crashed almost 15% yesterday after the company shocked investors with a bleak 2026 outlook that wiped out any optimism from its recent Wegovy pill launch.
The Danish drugmaker pre-released guidance indicating that both sales and operating profit could decline by 5%-13% in 2026, far worse than Wall Street expected.
The announcement came just weeks after Novo Nordisk stock had rallied on strong early sales of its new oral Wegovy pill.
CEO Mike Doustdar told CNBC that the guidance reflects “significantly lower U.S. pricing” for Wegovy as the company seeks to compete with lower-cost compounding pharmacies and rival Eli Lilly.
The new Wegovy pill starts at just $149 per month, a fraction of what the injectable version cost a year ago.
“People should expect that it goes down before it comes back up,” Doustdar said. “We are creating affordability for millions of patients that are right now in need of GLP-1 products but simply could not afford it. To do that short term, you have to take a headwind.”
The pricing pressure comes from multiple directions. Compounding pharmacies have been selling knockoff versions of semaglutide (the active ingredient in Wegovy and Ozempic) at much lower prices.
Eli Lilly is also aggressively competing in the weight-loss market. Novo Nordisk also struck a deal with President Trump recently to offer discounted prices for Medicare, Medicaid, and a new government website, TrumpRx.gov.
Making matters worse, Novo’s U.S. chief David Moore, who led the successful Wegovy pill launch, is leaving the company for personal reasons. He’ll be replaced by Jamie Miller, formerly with UnitedHealth Group.
See analysts’ growth forecasts and price targets for Novo Nordisk stock (It’s free!) >>>
What the Market Is Telling Us About NVO Stock
The plunge in Novo Nordisk stock shows investors are deeply concerned about the company’s near-term profitability as it sacrifices pricing to gain market share.
This marks the second major guidance cut in less than a year. In July 2025, Novo slashed its full-year outlook, sending shares down 23% in a single day.
Barclays analysts noted that some might call this a “kitchen sink” guide that will be beaten, “though we note the same was said last year, and this proved not to be the case.”
HSBC analyst Rajesh Kumar raised a key question: Will the recovery be a “Nike swoosh” (quick rebound) or “U-shaped” (prolonged pain before recovery)?
The timing is particularly painful because Novo Nordisk stock had just rallied 9% in January after reporting strong early sales for the Wegovy pill.
In just the first four days, retail pharmacies filled over 3,000 prescriptions, not counting Novo’s own pharmacy channel. Patients in clinical trials lost an average of 17% of their body weight on the pill.
But as Doustdar admitted, “No matter how well it does in the initial period, the price hit on the existing business trumps the great pill launch that we’ve had.”
Novo Nordisk stock has now fallen nearly 50% from its peak in 2025, marking the company’s worst year on record.
The company also made unprecedented leadership changes, appointing its first non-Danish CEO and bringing back former CEO Lars Rebien Sørensen as chairman of the board, a move some described as a power grab.
When asked if Novo Nordisk was in crisis, Doustdar said no, adding that “while we acknowledge 2025 presented significant challenges affecting our performance and share price, those adversities have also made us more resilient.”
The market clearly isn’t convinced yet.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Novo Nordisk Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
